NCT07384390

TH-CAR-027 for Grade 4 Gliomas

An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects With Recurrent or Progressive Grade 4 Glioma

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 21 (estimated)
• Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open-Label, dose-escalation, multiple administration, exploratory clinical study to evaluate the safety, tolerability, and anti-tumor activity of TH-CART-027 cell injection in subjects with recurrent or progressive grade 4 glioma

Conditions

• R/R Grade 4 Glioma

Interventions

Type	Name	Description
DRUG	TH-CART-027	Multiple-dosing, intratumoral and/or intraventricular infusion

Timeline

• Start date: 2026-01-30
• Primary completion: 2028-08-31
• Completion: 2029-08-31
• First posted: 2026-02-03
• Last updated: 2026-02-04